VMVasiliki Mamali

Vasiliki Mamali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vasiliki Mamali has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rectal colonization with multidrug-resistant organisms and risk for bloodstream infection among high-risk Greek patients

    by Polyxeni Karakosta, Georgios Meletis, Elisavet Kousouli, Efthymia Protonotariou, Aikaterini Tarpatzi, Sophia Vourli, Panagiota Christina Georgiou, Vasiliki Mamali, Lemonia Skoura, Olympia Zarkotou, et al.

    Background Studies link multidrug-resistant organism (MDRO) rectal colonization to increased infection risk, data from Greece, a country with high rates of MDRO, are limited. Methods We assessed bloodstream infection (BSI) risk following rectal colonization by MDROs across three Greek hospitals (2019–2022). Results Of 4,370 inpatients, 31.1% were colonized by carbapenem-resistant Enterobacterales (CRE), 30.1% carbapenem-resistant Acinetobacter baumannii (CRAB), 5.8% carbapenem-resistant Pseudomonas aeruginosa (CRPA), 28.4% vancomycin-resistant enterococci (VRE). Subsequent BSI from the same MDRO species was developed in 15.6% of CRE, 19.7% of CRAB, 9.2% of CRPA and 3.5% of VRE carriers. Previous rectal colonization increases significantly MDRO BSI risk [RR (95%CI): CRE 5.2 (3.9–6.8), CRAB 2.7 (2.2–3.3), CRPA 9.6 (5.8–16.0), VRE 2.5 (1.5–4.2)]. Conclusion Clinicians should consider MDRO carriage information for selecting empiric treatment.


  • Open Access

    2076. Intestinal colonization with multidrug-resistant organisms, horizontal transmission and risk for bloodstream infection

    by Polyxeni Karakosta, Georgios Meletis, Elisavet Kousouli, Efthymia Protonotariou, Sophia Vourli, Panagiota Christina Georgiou, Vasiliki Mamali, Lemonia Skoura, Olympia Zarkotou, Spyros Pournaras

    The association between rectal colonization and subsequent bloodstream infections (BSI) by multidrug-resistant organisms (MDROs) remains to be clarified. We aimed to investigate the relative risk of BSI in rectal carriers of MDROs and in the case of carbapenem-resistant Enterobacteriaceae (CRE), whether BSI was due to the patient’s own colonizing strain. We retrospectively included all adult inpatients hospitalized from Jan 2019 to Dec 2022, in ICUs or medical wards of 3 Greek hospitals (Athens: “Attikon” Hospital, Piraeus: Tzaneio Hospital, Thessaloniki: AHEPA Hospital), who were screened for intestinal MDRO carriage at admission and weekly. Screening was performed by selective media and immunochromatography for the carbapenemase in CRE. Patients were followed up for BSI by the same colonizing organism; relative risk (95% CI) was estimated after adjustment for ICU hospitalization and age. MDROs included CRE, carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA) and vancomycin-resistant enterococci (VRE). The CRE-colonizers and BSI-pathogens were analyzed for carbapenemase type to identify potential similarities. Rectal colonization with MDROs and the risk for BSI from the same pathogen Carbapenemase types in rectal carriers of CRE who developed subsequent BSI with the same pathogen Intestinal colonization by MDROs was associated with increased risk of BSI by the colonizing bacteria. Clinicians should evaluate this information for empiric treatment, while genome-wide data are needed to substantiate horizontal transmission. All Authors: No reported disclosures

  • Open Access

    2479. Impact of the COVID-19 pandemic on the hospital acquisition of multidrug-resistant organism in two Greek hospitals

    by Polyxeni Karakosta, Elisavet Kousouli, Sophia Vourli, Panagiota Christina Georgiou, Vasiliki Mamali, Olympia Zarkotou, Spyros Pournaras

    COVID-19 pandemic pushed back progress for combating antimicrobial resistance (AR). We aimed to provide a proxy measure for MDRO Hospital Acquisition in two Hospitals following COVID-19 pandemic. Active surveillance for MDROs recovered from any specimen collected >3 days post-admission, using laboratory data without patient’s clinical evaluation was conducted from Jan 2019 to Dec 2022 in Attikon & Tzaneio hospitals. MDROs included carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR Acinetobacter baumannii (CRAB), CR Pseudomonas aeruginosa (CRPA), vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Adult inpatients hospitalized in ICUs or non-ICU wards participated in the study. Surveillance definitions of MDRO Laboratory-Identified (LabID) Event and MDRO Infection/Colonization Incidence Density Rate (IDR) were based on the CDC MDRO/CDI Module criteria (January 2023). Patient days and susceptibility data of isolated CRE were collected monthly. Incidence rate ratio (95% CI) was calculated to examine changes in rates from 2019 (pre-pandemic) to 2020, 2021 and 2022 (pandemic). MDRO Infection/Colonization IDR has further deteriorated during the pandemic with CRE and CRAB having leading role. All Authors: No reported disclosures

  • Performance of the β LACTA™ test for rapid detection of expanded-spectrum cephalosporin-non-susceptible Enterobacteriaceae

    by Georgia Vrioni, Vasiliki Mamali, Olympia Zarkotou, Evangelia Voulgari, Evangelia Dimitroulia, Katerina Themeli-Digalaki, Spyros Pournaras, Athanassios Tsakris